secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2026-08-06T20:06:01+00:00
Accession:  0001193805-26-001039
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q2 net loss $23.8M; regains KOSTAIVE rights; ARCT-032 Phase 3 decision Q4 2026
--------------------------------------------------------------------------------

- Net loss of $23.8M ($0.84/share) vs $9.2M ($0.34/share) in Q2 2025; revenue fell to $3.0M from $28.3M due to CSL Seqirus termination.
- Regained global rights to KOSTAIVE and infectious disease portfolio from CSL Seqirus; received $12M cash and $16M in released liabilities.
- ARCT-032 (CF) Phase 2 enrollment on schedule; decision to proceed to Phase 3 expected Q4 2026; Thermo Fisher collaboration for Phase 3.
- ARCT-810 (OTC deficiency) Phase 2 enrollment and dosing completed; data and regulatory plan expected Q3 2026.
- Cash and cash equivalents $191.5M as of June 30, 2026; cash runway over 2.5 years through year end 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/0001193805-26-001039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380526001039/e665679_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-001039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer